European countries differ substantially in the predictability, speed, evidence burden, and complexity of obtaining reimbursement and enabling routine hospital use of medical devices. This online seminar will present the key findings of the MTRC Reimbursement, Policy & HTA Attractiveness Index 2026, which compares 12 European markets and identifies Germany, Denmark, and Switzerland as the leading markets. It will explain how manufacturers can use the findings to support country prioritization, launch sequencing, evidence planning, and time-to-revenue expectations. The seminar will be delivered by Oleg Borisenko, MD, PhD, on 27 August 2026 at 17:00 CET.

On August 3, 2026, NHS England released an updated work plan for the development of Clinical Commissioning Policies for specialised services, reflecting the status as of July 2026. The update includes four new MedTech-related policies in the radiotherapy and orthopedic fields, and the initiation of two new policies in the gastrointestinal and reproductive health areas. The status of ongoing policies has been revised, and two policies for proton beam therapy have been discontinued.

In July 2026, the French Ministry of Health granted early coverage under the PECAN scheme to a digital medical device (Poppins Clinical) for the rehabilitation of specific learning disorders involving reading deficits. Since the scheme's inception in 2023, all devices granted early coverage have been intended for remote patient monitoring. The decision on Poppins Clinical marks the first PECAN coverage of a therapeutic digital medical device.

In July 2026, the Dutch government allocated €102.5 million to strengthen the national MedTech ecosystem. The initiative responds to the MedTech Growth Plan and aims to address healthcare workforce shortages and rising demand for care by supporting innovation, implementation, and closer cooperation among industry, healthcare providers, and research institutions.

The State-Regions Conference formally approved the draft Ministerial Decree updating the maximum national reimbursement tariffs for outpatient specialist services and prosthetic aids under the Essential Levels of Care (LEA) catalog. The revision covers 448 outpatient specialist services and 222 prosthetic-care codes. The draft does not revise the laboratory test tariffs.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its EU HTA Publications Digest. In a recent publication, Aballéa et al. critically reviewed the EU HTA Coordination Group guidelines on direct and indirect treatment comparisons in the context of joint clinical assessments.

In July 2026, an independent review of UK pathology services was published. It covers seven main areas: international experience, the devolved UK nations, quality, workforce, patient access, digital and diagnostic infrastructure, and value and funding. Among the six system-wide priorities, the report recommends aligning digital, workforce, and funding reforms into a single implementation program, moving towards activity-aligned funding through a price-per-test tariff model.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Publications Digest. In a recent publication, Bralić et al. conducted a scoping review of methodologies for generating and evaluating evidence for high-risk and innovative medical devices and in vitro diagnostics in the EU.

In July 2026, the French National Authority for Health established MiMED department within its Directorate for Evaluation and Access to Innovation. The new department will modernize health technology assessment methods, strengthen the use of real-world data, and support France's contribution to European HTA coordination.

As of July 2026, the Aragon Institute of Health Sciences (IACS), one of Spain’s regional health technology assessment bodies, is conducting several HTAs in areas including diagnostic imaging, digital health, and in vitro diagnostics.

Our goal at MTRC is to inform the decision-making of our clients and to support their market access activities. Below is a snapshot of our planned activities for the next two weeks. This can help our existing and prospective clients understand the potential scope of our support better. From the week of July 27th, we plan to work on 13 projects. Review the complete list of planned activities in this post.

On July 10, 2026, the German Bundestag passed the Statutory Health Insurance (SHI) Contribution Rate Stabilization Act (GKV-Beitragssatzstabilisierungsgesetz). During the parliamentary process, additional fiscal measures were incorporated into the legislation after it was approved by the Federal Cabinet to close the funding gap that had widened in the interim.